Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
D 170.471 7.82% 12.37
NVAX closed down 13.89 percent on Thursday, March 4, 2021, on 1.64 times normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical NVAX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 9.02%
MACD Bearish Centerline Cross Bearish 9.02%
Expansion Pivot Sell Setup Bearish Swing Setup 9.02%
Lower Bollinger Band Walk Weakness 9.02%
Multiple of Ten Bearish Other 9.02%
Multiple of Ten Bullish Other 9.02%
Wide Bands Range Expansion 9.02%
Below Lower BB Weakness 9.02%
Down 3 Days in a Row Weakness 9.02%
Lower Bollinger Band Touch Weakness 9.02%
Older End-of-Day Signals for NVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% about 1 hour ago
Trending on StockTwits about 2 hours ago
60 Minute Opening Range Breakout about 2 hours ago
Down 5% about 3 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novavax, Inc. Description

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Influenza Coronavirus Vaccine Vaccination Influenza Vaccine Influenza Vaccines Rabies Seasonal Influenza Novavax

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 331.5388
52 Week Low 6.77
Average Volume 4,560,316
200-Day Moving Average 123.53
50-Day Moving Average 187.95
20-Day Moving Average 257.11
10-Day Moving Average 224.69
Average True Range 25.65
ADX 31.04
+DI 18.35
-DI 42.98
Chandelier Exit (Long, 3 ATRs ) 254.60
Chandelier Exit (Short, 3 ATRs ) 224.33
Upper Bollinger Band 340.78
Lower Bollinger Band 173.43
Percent B (%b) -0.09
BandWidth 65.09
MACD Line -1.81
MACD Signal Line 14.48
MACD Histogram -16.291
Fundamentals Value
Market Cap 10.06 Billion
Num Shares 63.7 Million
EPS -8.60
Price-to-Earnings (P/E) Ratio -18.39
Price-to-Sales 30.36
Price-to-Book 77.25
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 220.08
Resistance 3 (R3) 223.40 206.05 209.75
Resistance 2 (R2) 206.05 190.27 204.40 206.30
Resistance 1 (R1) 182.08 180.52 173.41 178.76 202.86
Pivot Point 164.73 164.73 160.40 163.08 164.73
Support 1 (S1) 140.76 148.95 132.09 137.44 113.34
Support 2 (S2) 123.41 139.20 121.76 109.90
Support 3 (S3) 99.44 123.41 106.45
Support 4 (S4) 96.12